Anavex Life Sciences Corp (AVXL)

[Investor2014]

Don't forget it is a blinded trial and that Missling is reluctant to spend an interim look risking problems with the statistical power and chances of approval at the end of the pivotal trial. I agree with Missling.

OLE data could be an option, but not too many patients have completed 48 weeks of OLE at this point in time.

Think we need to be prepared to wait for 2nd half of 2022 for the AD readout.